In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

ArQule completed IPO of 2.875mm shares raising proceeds $31.3mm

Executive Summary

Three-year old rational drug design company ArQule completed its IPO of 2.875mm shares of common stock (including an overallotment of 375,000 shares) at $12 a share, raising net proceeds of about $31.3mm. ArQule increased the offering from 2mm shares.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies